Atai Life Sciences completes combination between atai Life, Beckley Psytech

Atai Beckley announced the successful completion of the strategic combination between atai Life Sciences (ATAI) and Beckley Psytech in an all-share transaction. The combined company brings together world-class science and clinical expertise with a pipeline of investigational psychedelic-based neuroplastogens designed to address some of the most urgent unmet needs in mental health. AtaiBeckley will be led by CEO and Co-Founder Dr. Rao. He will be joined by an executive team with deep expertise in neuroscience, psychiatry, and drug development including: Anne Johnson, CPA as Chief Financial Officer, Rob Conley, M.D. as Chief Research & Development Officer, Gerd Kochendoerfer, Ph.D. as Chief Operating Officer, Kevin Craig, M.D. as Chief Medical Officer, Glenn Short, Ph.D. as Chief Scientific Officer and Ryan Barrett as Chief Legal and Business Officer. Christian Angermayer, Founder of atai, will continue to serve as Chairman, and Scott Braunstein, M.D., has been appointed Vice Chairman and designated Lead Independent Director. All members of the atai Board will remain on the AtaiBeckley Board and they will be joined by Beckley Psytech Board Members Cosmo Feilding Mellen and Robert Hershberg, M.D., Ph.D. In connection with the AtaiBeckley transaction, Beckley’s shareholders, certain Beckley equity award holders and certain Beckley consultants will be issued approximately 105 million new AtaiBeckley shares or replacement awards covering AtaiBeckley shares. The newly issued shares equate to approximately 28% of shares outstanding of the combined company.